Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
Verastem Oncology (Nasdaq: VSTM) (the "Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET.
To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative.
Following the event, an archived replay of the fireside chat will be available on the investors section of the Company's website at www.verastem.com.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI...
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...
